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Research MYEOV (myeloma overexpressed gene) drives colon 
cancer cell migration and is regulated by PGE2
Garrett Lawlor1, Peter P Doran2, Padraic MacMathuna1 and David W Murray*2
Abstract
Introduction: We have previously reported that Myeov (MYEloma OVerexpressed gene) expression is enhanced in 
colorectal cancer (CRC) and that it promotes CRC cell proliferation and invasion. The role of Myeov in CRC migration is 
unclear. ProstaglandinE2 (PGE 2) is a known factor in promoting CRC carcinogenesis. The role of PGE 2 in modulating 
Myeov expression has also not been defined.
Aim: To assess the role of Myeov expression in CRC cell migration and to evaluate the role of PGE 2 in Myeov bioactivity.
Methods: siRNA mediated Myeov knockdown was achieved in T84 CRC cells. Knockdown was assessed using 
quantitative real time PCR. The effect of knockdown on CRC cell migration was assessed using a scratch wound healing 
assay. Separately, T84 cells were treated with PGE 2 (0.00025 μ M, 0.1 μ M and 1 μ M) from 30 min to 3 hours and the 
effect on Myeov gene expression was assessed using real time PCR.
Results: Myeov knockdown resulted in a significant reduction in CRC cell migration, observable as early as 12 hours (P 
< 0.05) with a 39% reduction compared to control at 36 hours (p < 0.01). Myeov expression was enhanced after 
treatment with PGE 2, with the greatest effect seen at 60 mins for all 3 PGE 2 doses. This response was dose dependent 
with a 290%, 550% & 1,000% increase in Myeov expression for 0.00025 μ M, 0.1 μ M and 1 μ M PGE 2 respectively.
Conclusion: In addition to promoting CRC proliferation and invasion, our findings indicate that Myeov stimulates CRC 
cell migration, and its expression may be PGE 2 dependant.
Introduction
Colorectal cancer is a heterogeneous disease arising from
a complex series of molecular changes [1]. In 1990,
Fearon and Vogelstein described the molecular basis of
colorectal cancer as a multi-step model of carcinogenesis
[2]. The model describes the accumulation of genetic
events, each conferring a selective growth advantage to
an affected colon cell, including inactivation of tumour
suppressor genes and activation of oncogenes.
Using a bioinformatics approach we have identified
genes with enhanced expression in colorectal cancer tis-
sue [3,4]. Myeov, (MYEloma OVerexpressed gene) was
initially noted for its association with a subset of multiple
myeloma cell lines [4,5] and it has also been implicated in
oesophageal squamous cell carcinomas [6] and breast
cancer [7]. Myeov is co-amplified with cyclin D1, a
known oncogene [5]. We have previously shown Myeov
to play a role in gastric cancer cell proliferation and inva-
sion [3].
Our group has demonstrated a role for Myeov in the
pathogenesis of colorectal cancer (CRC), noting a 20-fold
increase in Myeov expression in CRC in comparison with
normal colorectal tissue [3]. We have also confirmed that
Myeov is upregulated in CRC ex vivo using tissue from
normal colonic mucosa, adenomas, and carcinomas [3].
Our  In vitro RNA interference/knockdown studies, in
which Myeov expression was inhibited, revealed a role for
Myeov in driving CRC cell proliferation and invasion.
H o w e v e r ,  t h e  r o l e  o f  M y e o v  e x p r e s s i o n  i n  C R C  c e l l
migration has not been elucidated. We hypothesise,
because of its established role in tumour cell invasion,
that Myeov is also important for tumour cell migration.
The mechanism underlying Myeov expression remains
unclear.
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I n  a n  e f f o rt  t o  i d e n t i fy  u p s t r e a m  e f f ec t o r s  o f  M y e o v
expression, we assessed the effect of Prostaglandin E2
(PGE 2) on Myeov. PGE 2 is a well-established mediator in
cancer progression, particularly in CRC. It has been
shown to enhance intestinal adenoma growth in ApcMin
mice models of CRC [8]. Driven by COX-2, PGE 2 can
enhance tumour growth by binding its receptors and acti-
vating signalling pathways which control cellular prolifer-
ation, migration, apoptosis, and angiogenesis, key
features of malignancy [9]. We investigated the possibility
that PGE 2  may mediate the enhanced expression of
Myeov in CRC. Consequently, the objectives of our study
were two-fold; firstly, to assess the role of Myeov gene
knockdown on CRC cell migration in vitro; secondly, to
evaluate the effect of PGE 2 on Myeov mRNA expression
in CRC.
Materials and methods
Cell culture
The T84 cell line obtained from the European collection
of cell cultures was used in this study as it is an estab-
lished in vitro experimental model of colorectal carci-
n o m a .  T h e  c e l l  w e r e  c u l t u r e d  i n  D u l b e c c o ’ s  m o d i f i e d
Eagle’s medium-F12, with 1 U/ml penicillin, 1 lg/ml
streptomycin, and 10% fetal bovine serum under standard
conditions.
siRNA knockdown
The functional role of Myeov was assessed using gene
knockdown with small interfering RNA (siRNA)
designed and synthesized for Myeov knockdown (Qiagen
Inc., CA, USA). The siRNA had the following sequences:
Myeov sense, 50-GGA UGU AAG UUA UCA ACU A-30;
Myeov antisense, 50-UAG UUG AUA ACU UAC AUC C-
30. A chemically synthesized non-silencing siRNA duplex
with the following sequence; sense, 50-UUC UCC GAA
CGU GUC ACG U-30; antisense, 50-ACG UGA CAC
GUU CGG AGA A-30 that had no known homology with
any mammalian gene was used to control for non-specific
silencing events. Gene knockdown was achieved in T84
cells. Briefly, 4 × 10 4 cells were incubated under standard
conditions overnight. 5 μg of each siRNA was then mixed
with 30 μl of RNAifect (Qiagen) and was added drop
wise. Cells were incubated for 48 h again under standard
conditions before being assayed.
RNA preparation and PCR
TRIzol (Sigma-Aldrich, Ireland) was used to extract RNA
from cells. Reverse transcription was achieved using
AMV reverse transcriptase (Invitrogen Ltd., UK). Real-
time RT-PCR was performed using a Rotor Gene (Cor-
bett Research, Australia). GAPDH, which was amplified
in parallel with the genes of interest, served as a house-
keeping gene. All measurements were performed in trip-
licate. The oligonucleotide primers and probes employed
in this study were: MYEOV forward primer: CCT AAA
TCC AGC CAC GTC AT, reverse primer; GAC ACA
CCA CGG AGA CAA TG, GAPDH forward primer:
GAA GGT GAA GGT CGG AGT TC, reverse primer
GAA GAT GGT GAT GGG ATT TC.
Cell migration 'Scratch Assay'
Following Myeov knockdown, a "scratch" was placed in a
confluent T84 cell monolayer using a 10 μl micropipette
tip [10]. Cell migration over this wound scratch was mon-
itored by photographing at 1, 6, 12, 24 and 36 hours. Sub-
sequent image analysis involved measuring scratch width
at 5 random points. Average scratch width and standard
deviation was calculated for each time point. Cells were
photographed using a × 10 objective lens. Carnoy soft-
ware (Biovolution) was used to measure the pixel width
of the scratches.
The effects of PGE 2 on Myeov expression
T84 CRC cells were treated with increasing concentra-
tions (0.00025 μM, 0.1 μM, 1 μM) of PGE 2  (Sigma
Aldrich, Ireland) for 30, 60 and 180 mins. The concentra-
tions of PGE 2 used reflect the optimal in-vitro concentra-
tion to induce cellular responses as noted in a number of
studies [11-14]. RNA extraction and real time PCR were
performed as described above.
Statistics
All analyses were performed independently in triplicate.
Students paired t-test was used to compare groups with a
P value < 0.05 indicating statistical significance.
Results
The effect of Myeov gene knockdown on CRC cell migration
In order to establish the role of Myeov in colorectal can-
cer cell migration we performed targeted knockdown
using siRNA. A T84 cell line model of colorectal cancer
was used. Successful knockdown of Myeov mRNA
expression in T84 cells using siRNA was confirmed using
quantitative real time PCR (Figure 1A). A 74% reduction
in Myeov mRNA expression was observed in knockdown
cells in comparison with control cells 48 hr post transfec-
tion (P < 0.05). In order to investigate the effect of Myeov
depletion on T84 colorectal cancer cell migration, scratch
wound healing assays were performed. Myeov knock-
down resulted in decreased T84 colorectal cancer cell
migration. Myeov knockdown resulted in a 25%, 41%, and
39% reduction in T84 colorectal cancer cell migration
was observed at 12, 24 and 36 hrs respectively compared
to control cells (P < 0.05) (Figure 1C).Lawlor et al. Journal of Experimental & Clinical Cancer Research 2010, 29:81
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The effect of PGE2 on Myeov expression
In order to investigate the effect of PGE 2 on Myeov gene
expression in colorectal cancer, T84 colorectal cancer
cells were treated with varying doses of PGE 2 for varying
times in vitro and Myeov mRNA expression was moni-
tored using quantitative real time PCR. Treatment of T84
cells with PGE 2 for 24 hr resulted in increased Myeov
expression however the maximum effect occurred at 60
mins (Figure 2A &2B). Furthermore this effect was dose-
dependent. At 60 mins, 0.00025 μ M PGE 2 increased
Myeov gene expression by 289%, 0.1 μM PGE 2 increased
Myeov expression by 547% and 1.0 μM PGE 2 increased
Myeov expression by 961% (P < 0.05). Treatment with
PGE 2 for 30 min resulted in decreased Myeov expression
with 1.0 μM treatment having a significant inhibitory
effect, decreasing Myeov expression by 99% (P < 0.01)
(Figure 2B).
Discussion
Colorectal cancer has a significant morbidity and mortal-
ity, being the fourth most common cancer worldwide
[15]. Defining the pathways that drive colorectal cancer
will provide a better understanding of neoplastic progres-
sion, and may potentially identify targets for therapeutic
intervention. Myeov expression has previously been
shown to be enhanced in myeloma as well as breast,
esophageal and gastric cancers [7,9]. We have employed
Digital Differential Display (DDD) a bioinformatic tool,
to identify Myeov as a novel colorectal cancer associated
gene [3]. Briefly, we used DDD to compare expressed
sequence tags (ESTs) between normal colorectal and can-
cer tissue, thereby identifying differentially expressed
genes. Myeov was shortlisted for further investigation
and we demonstrated enhanced Myeov expression in col-
orectal cancer and that it promotes tumour proliferation
and invasion [3], key hallmarks of metastatic cancer.
These datasets support the important role of Myeov in
this disease.
Gene knockdown using siRNA represents an excellent
tool to assess the functional importance of cancer related
genes in vitro. We have previously employed siRNA to
knockdown Myeov in colorectal and gastric cancer cell
lines and have shown knockdown to result in decreased
cell proliferation and invasion [3,9]. Using this technol-
ogy, the current study further supports the functional
Figure 1 (A) Confirmation of Myeov knockdown. Myeov mRNA expression in control and siRNA treated cells was quantitated using real time PCR. 
(* = p < 0.05). (B) Representative images of the wound healing scratch assay. The lines represent measurements made to assess reduction in "scratch" 
width as a marker of migration. (C) Effect of Myeov knockdown on cell migration over time (* P < 0.05. ** P < 0.01).
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importance of Myeov in CRC by showing that it drives
colorectal cancer cell migration, a key process in the
malignant phenotype. This data consolidates our previ-
ous reports that Myeov drives both proliferation and
invasion. This new data illustrates a further role for
Myeov in the motility of colorectal cancer cell and key
hallmark of metastatic tumour cells.
Having established Myeov as a key player in CRC cell
biology, we investigated whether Myeov was a down-
stream effector of COX/PGE 2 bioactivity. PGE 2 is a well
established player in the progression of CRC and has
been shown to induce increased proliferation, migration,
and invasiveness of CRC cells [16]. We hypothesise that
enhanced COX/PGE 2  bioactivity in CRC leads to
increased levels of Myeov and therefore increased inva-
sion and migration. We have demonstrated in this study
that treatment with PGE 2 enhances the expression of
Myeov. Although the signalling mechanisms connecting
PGE  2  signalling and Myeov transcription remain
unknown, our findings support the hypothesis that
Myeov is in part PGE 2 regulated and contributes to the
downstream oncogenic activity of COX. PGE 2 has been
shown to drive CRC cell migration and enhanced Myeov
expression may at least in part mediate this process [16].
The precise signalling and transcriptional mechanisms at
p l a y  h e r e  n e e d  t o  b e  f u r t h e r  d e c i p h e r e d .  I t  h a s  b e e n
shown that PGE 2-mediated CRC cell migration is related
to the intracellular activation of EGFR by PGE 2 [17]. Fur-
ther work will clarify if Myeov expression is regulated by
PGE 2 in a similar manner. Interestingly, we also quanti-
tated the levels of secreted PGE 2 in Myeov knockdown
and control cells however no significant difference was
observed, confirming that the regulation of PGE 2 expres-
sion is not downstream of Myeov bioactivity (data not
shown).
These findings further define the role for Myeov bioac-
tivity in colorectal carcinogenesis. Ongoing studies into
Myeov expression will expand this pathway to reveal
newer insights into colorectal cancer progression and
possibly enable a potential therapeutic based on targeting
Myeov.
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